Article Text

AB0489 Serum chemokines in rheumatoid arthritis patients treated with repeated infusions of infliximab
  1. P.A. Klimiuk,
  2. S. Sierakowski,
  3. I. Domyslawska,
  4. J. Chwiecko
  1. Department of Rheumatology and Internal Diseases, Medical University of Bialystok, Bialystok, Poland


Background Chemokines have an important role in the infiltrating of rheumatoid synovium with mononuclear cells, leading to the initiation and progression of the rheumatoid arthritis (RA).

Objectives We studied the effects of the multiple infusions of infliximab, a chimeric anti-tumor necrosis factor alpha (anti-TNF-α) antibody, on the serum chemokines levels in patients with active RA.

Methods RA patients were supposed to receive 9 infusions of infliximab (3mg/kg) at weeks 0, 2, 6, and every 8 weeks thereafter with the same dose. All patients continued treatment with methotrexate (MTX) (7.5-20mg/week). Serum concentrations of interleukin-8 (IL-8), RANTES (regulated upon activation, normal T cell expressed and secreted) and monocyte chemoattractant protein-1 (MCP-1) were assessed by ELISA on weeks 0, 2, 6, 14, 38, prior to infusion, and additionally on week 62.

Results Initial infusion of infliximab caused reduction in serum IL-8, RANTES and MCP-1 (in all cases p<0.001) levels. Subsequent infliximab administrations also significantly decreased serum chemokines levels, but was less effective. Prior to the first infliximab infusion serum concentrations of studied chemokines correlated with markers of RA activity such as the erythrocyte sedimentation rate (ESR) or CRP levels, number of swollen joints and disease activity score (DAS). Following next drug infusions such associations were far less significant. Infliximab treatment induced a significant reduction in the number of monocytes observed through the whole study (in all cases p<0.05).

Conclusions Anti-TNF-α antibody therapy accompanied by MTX, beside a rapid clinical improvement, reduced serum chemokines concentrations in RA patients. Subsequent administrations of infliximab sustained chemokines decrease, although to a lesser extent than the first two doses of infliximab.

Disclosure of Interest None Declared

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.